Genetic Mechanisms Underlying SARS-CoV-2 Infection and the Impact of COVID-19 on Cognitive Function

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04506229

Acronym

GenCov

Enrollment

Registered

2020-08-10

Start date

2020-08-20

Completion date

2021-09-30

Last updated

2020-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid19

Brief summary

There is a considerable variation in the disease behavior in terms of contracting the infection, manifesting none to a range of symptoms and severity of the infection among individuals exposed to or infected with SARS-CoV-2 virus, the causative organism of COVID-19. Although the respiratory system appears to be the primary target of this virus infection, emerging evidences suggests involvement of extra-pulmonary organs including central nervous system. We aim to compare the genetic profile of individuals with vs without COVID-19 after being exposed to infected cases. Additionally, we will assess the cognitive function in covid-19 positive cases with vs. without neurological symptoms at the time of infection and 1-month follow-up using the Montreal Cognitive Assessment (MoCA) questionnaire.

Interventions

GENETICWhole exome sequencing

MoCA survey to evaluate cognitive function in COVID-19 positive cases with vs without neurological symptoms

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Male or female over 18 years of age at the time of enrollment 2. Have symptoms of COVID-19 (with or without hospitalization) or contact history 3. Willing to undergo nasopharyngeal swab test for viral-RNA at baseline (in non-hospitalized cases) and the MoCA survey at baseline and 1-month follow-up

Exclusion criteria

1. Unwilling to provide informed consent 2. MoCA score ≤17 at baseline 3. Patients with clinical diagnosis of dementia 4. Impaired consciousness

Design outcomes

Primary

Measure	Time frame	Description
Genetic variants with vs without COVID-19	1 day	Evaluate variants in the following known COVID-associated genes, ACE2R, IFITM, HLA-B 46, HLA-B 15, Toll Like Receptor and IFN-1, LIST, Perforin and mutations in Chromosome 3p21.31 along with novel genetic variants.
Cognitive function at baseline	1 day	Assess the cognitive status at baseline using MoCA survey in patients with vs without neurological symptoms

Secondary

Measure	Time frame	Description
Change in cognitive function at 1 month	1 month	change in the MoCA score from baseline in patients with vs without neurological symptoms
Genetic analysis	1 day	compare the genetic variants in patients with no or mild to moderate vs severe symptoms

Countries

United States

Contacts

Primary ContactSanghamitra Mohanty

mitra1989@gmail.com5127842651

Backup ContactBryan MacDonald

5125447252

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026